Direkt zum Inhalt
Merck

SML0042

Lazabemide hydrate

≥97% (HPLC)

Synonym(e):

N-(2-Aminoethyl)-5-chloro-2-pyridinecarboxamide hydrate, Ro 19-6327 hydrate

Slide 1 of 1
Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Über diesen Artikel

Empirische Formel (Hill-System):
C8H10ClN3O · xH2O
CAS-Nummer:
103878-84-8
Molekulargewicht:
199.64 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329825112
UNSPSC Code:
12352200
MDL number:
MFCD20488051

Wichtige Dokumente

Gesamtdokumentation anzeigen

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

InChI

1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2

SMILES string

O.NCCNC(=O)c1ccc(Cl)cn1

InChI key

JYWYNPKXSLPWGV-UHFFFAOYSA-N

assay

≥97% (HPLC)

form

powder

storage condition

desiccated

color

white to tan

solubility

DMSO: ≥22 mg/mL

originator

Roche

storage temp.

room temp

Quality Level

100

Verwandte Kategorien

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
C5976A7410SML0098
Lazabemide hydrate ≥97% (HPLC)

Sigma-Aldrich

SML0042

Lazabemide hydrate

CL 316,243 hydrate ≥98% (HPLC), powder

Sigma-Aldrich

C5976

CL 316,243 hydrate

Amiloride hydrochloride hydrate ≥98% (HPLC), powder

Sigma-Aldrich

A7410

Amiloride hydrochloride hydrate

Pinostilbene hydrate ≥95% (HPLC)

Sigma-Aldrich

SML0098

Pinostilbene hydrate

form

powder

form

powder

form

powder

form

powder

assay

≥97% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

200

Quality Level

100

storage temp.

room temp

storage temp.

room temp

storage temp.

room temp

storage temp.

2-8°C

solubility

DMSO: ≥22 mg/mL

solubility

H2O: 10 mg/mL, clear

solubility

H2O: 50 mg/mL, clear, yellow-green

solubility

DMSO: ≥13 mg/mL

storage condition

desiccated

storage condition

-

storage condition

-

storage condition

-

Application

Lazabemide hydrate may be used in cell signaling studies.

Biochem/physiol Actions

Lazabemide is a selective and reversible monoamine oxidase B (MAO-B) inhibitor and Anti-Parkinson. Also it inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Lazabemide is effective in treatment of Alzheimer′s disease[1] and in combination with nicotine replacement therapy aids in smoking cessation.[2]
Selective MAO-B inhibitor; Antiparkinson

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302,H319

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
071M4718V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

R Raddatz et al.
The Journal of pharmacology and experimental therapeutics, 292(3), 1135-1145 (2000-02-25)
A series of phenoxy-substituted methylimidazoline derivatives were synthesized and used to define the ligand recognition properties of the imidazoline-binding domain (IBD) on monoamine oxidase (MAO)-B and its role in substrate processing. The rank order of potency for selected compounds in
Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
A M Cesura et al.
Advances in neurology, 80, 521-528 (1999-07-20)
Javier Ballesteros et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 18(1), 55-61 (2007-06-16)
Previous studies have reported negative findings for the association among brain monoamine oxidase B (MAO-B) and suicidal behaviour. However those studies did not adequately control their main results for the influence of confounding variables such as age at death. We
V Petegnief et al.
Neuroscience, 94(1), 105-115 (1999-12-29)
Previous data from our laboratory indicate that 25 mM ibotenic acid induces intracellular calcifications in the rat basal forebrain. Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was
Yuji Kitaichi et al.
European journal of pharmacology, 532(3), 236-245 (2006-02-21)
We investigated the effects of clorgyline [a selective MAO (monoamine oxidase inhibitor)-A inhibitor] and lazabemide (a selective MAO-B inhibitor) on extracellular serotonin, dopamine and noradrenaline concentrations in the medial prefrontal cortex after 1-week treatment with subchronic 0.2% or 0.05% Li2CO3
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung